Insider Trading June 15, 2026 04:37 PM

Ryan Specialty Director Kuczinski Accumulates Shares Amid Mixed Analyst Sentiment

Insider buying occurs as the stock navigates a 12.6% weekly surge and divergent analyst views on valuation and growth.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
RYAN

Anthony J Kuczinski, a director at RYAN SPECIALTY HOLDINGS, INC. (NYSE:RYAN), executed two share purchases in mid-June totaling $104,960. This activity coincides with a period of significant stock price movement and conflicting analyst outlooks regarding the company's valuation and growth trajectory.

Ryan Specialty Director Kuczinski Accumulates Shares Amid Mixed Analyst Sentiment
RYAN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Insider Accumulation: Director Kuczinski purchased $104,960 worth of shares in mid-June, bringing his direct holdings to 13,072 shares.
  • Valuation Divergence: While InvestingPro highlights an attractive PEG ratio of 0.23, Goldman Sachs and Wells Fargo cite concerns over price softening and weaker organic growth.
  • Shareholder Returns: Ryan Specialty Group increased its share repurchase program by $300 million, signaling a commitment to enhancing shareholder value through buybacks in 2026 and 2027.

Anthony J Kuczinski, serving as a director at RYAN SPECIALTY HOLDINGS, INC. (NYSE:RYAN), has executed a series of share acquisitions, reflecting a specific position in the company's equity. The transactions, completed in mid-June, involved the purchase of Class A Common Stock across two distinct dates. The aggregate value of these acquisitions stands at $104,960.

The initial transaction took place on June 11, 2026. On this date, Mr. Kuczinski acquired 2,500 shares of the Class A Common Stock. The pricing for this batch of shares was reported as a weighted average of $34.83. The price range for these individual shares spanned from $34.56 to $35.06 per share. Following this, on June 12, 2026, he purchased an additional 500 shares. These subsequent shares were acquired at a weighted average price of $35.77, with the price range extending from $35.57 to $35.94 per share.

The timing of these insider purchases warrants attention, particularly given the recent market performance of the stock. Over the past week, the stock has experienced a surge of 12.6%. However, this recent gain does not offset a longer-term decline, as the stock remains down 33.7% over the last six months. According to analysis provided by InvestingPro, RYAN currently appears undervalued at these levels. The analysis highlights an attractive PEG ratio of 0.23, suggesting a potential valuation opportunity.

Following the completion of these transactions, Mr. Kuczinski's direct holdings in RYAN SPECIALTY HOLDINGS, INC. Class A Common Stock amount to 13,072 shares. This position provides a concrete data point regarding insider ownership levels.

Investors seeking deeper insights can access a comprehensive Pro Research Report on RYAN. This report is part of a coverage set that includes over 1,400 US equities, offering expert analysis and actionable intelligence. The ProPicks AI tool evaluates RYAN alongside thousands of other companies monthly using 100+ financial metrics. This AI-driven assessment looks beyond popularity to evaluate fundamentals, momentum, and valuation, identifying stocks with favorable risk-reward profiles based on current data. Notable past winners identified by this system include Super Micro Computer, which saw a gain of 185%, and AppLovin, which rose by 157%.

Broader market context reveals mixed analyst evaluations for Ryan Specialty Group. The company recently announced an increase in its share repurchase program by $300 million. This expansion follows the exhaustion of its previous authorization and reflects a strategic decision to enhance shareholder value through buybacks. Keefe, Bruyette & Woods maintained an Outperform rating on Ryan Specialty. The firm raised its price target to $44 from $42. This adjustment was based on revised earnings per share estimates and significant planned buybacks scheduled for 2026 and 2027.

Conversely, other analysts have adopted a more cautious stance. Goldman Sachs downgraded Ryan Specialty to Neutral from Buy. The firm cited concerns over prolonged price softening in the commercial property and casualty sectors. This softening could potentially impact the company's growth potential. Wells Fargo also downgraded the stock to Equal Weight from Overweight. The firm reduced its price target to $31 from $42. This downgrade was driven by expectations of weaker organic growth in the near term.

Ryan Specialty is currently targeting organic growth in the 4-6% range for the year. However, no growth is anticipated in the second quarter. These developments highlight varying analyst perspectives on the company's future performance. The stock closed at 35.34, reflecting a change of -0.30 or -0.84%. After hours trading showed a price of 35.34 with a change of 0.00 or 0.00%.


Key Points

  • Insider Accumulation: Director Kuczinski purchased $104,960 worth of shares in mid-June, bringing his direct holdings to 13,072 shares.
  • Valuation Divergence: While InvestingPro highlights an attractive PEG ratio of 0.23, Goldman Sachs and Wells Fargo cite concerns over price softening and weaker organic growth.
  • Shareholder Returns: Ryan Specialty Group increased its share repurchase program by $300 million, signaling a commitment to enhancing shareholder value through buybacks in 2026 and 2027.

Risks and Uncertainties

  • Commercial Sector Softening: Goldman Sachs warns of prolonged price softening in the commercial property and casualty sectors, which could negatively impact growth potential.
  • Near-Term Growth Slowdown: Wells Fargo highlights expectations of weaker organic growth in the near term, with no growth anticipated in the second quarter.
  • Long-Term Decline: Despite recent gains, the stock remains down 33.7% over the last six months, indicating ongoing downward pressure.

Risks

  • Commercial Sector Softening: Goldman Sachs warns of prolonged price softening in the commercial property and casualty sectors, which could negatively impact growth potential.
  • Near-Term Growth Slowdown: Wells Fargo highlights expectations of weaker organic growth in the near term, with no growth anticipated in the second quarter.
  • Long-Term Decline: Despite recent gains, the stock remains down 33.7% over the last six months, indicating ongoing downward pressure.

More from Insider Trading

Cytosorbents CEO Phillip Chan Executes $104K Stock Purchase Amid Earnings Miss Jun 15, 2026 Lovett William Radford II Offloads $2.05M in Dream Finders Homes Equity Jun 15, 2026 Zumiez Director Valletta Disposes of Shares Amidst Earnings Miss and Stock Decline Jun 15, 2026 Brian Sheth and Haveli Entities Acquire $1.99M of Blend Labs Stock Jun 15, 2026 Fractyl Health Director Ajay Royan Acquires Additional Shares Amid Clinical Milestones Jun 15, 2026